Combating endometriosis by blocking proteasome and nuclear factor-?B pathways

Basit Öğe Kaydı
dc.authoridTağluk, M. Emin/0000-0001-7789-6376
dc.authoridAYDIN, Nasuhi/0000-0003-3145-2432
dc.authorwosidTağluk, M. Emin/ABH-1005-2020
dc.authorwosidAYDIN, Nasuhi Engin/L-1607-2019
dc.authorwosidAydin, Nasuhi E/B-6536-2012
dc.authorwosidelter, koray/A-5082-2018
dc.authorwosidAYDIN, Nasuhi/O-9043-2016
dc.contributor.authorCelik, Onder
dc.contributor.authorHascalik, Seyma
dc.contributor.authorElter, Koray
dc.contributor.authorTagluk, M. E.
dc.contributor.authorGurates, Bilgin
dc.contributor.authorAydin, N. E.
dc.date.accessioned2024-08-04T20:31:00Z
dc.date.available2024-08-04T20:31:00Z
dc.date.issued2008
dc.departmentİnönü Üniversitesien_US
dc.description24th Annual Meeting of the ESHRE -- JUL 06-09, 2008 -- Barcelona, SPAINen_US
dc.description.abstractBACKGROUND: The objective of this study is to investigate the effect of pyrrolidine dithiocarbamate [PDTC; a nuclear factor-kappaB (NF-kappa B) inhibitor] and bortezomib (Velcade; a proteasome inhibitor) on the development of experimental endometriotic implants in rats. METHODS: Endometriosis was surgically induced in 30 rats using the method of Vernon and Wilson. Three weeks later the viability and volume of the implants were recorded and classified. Afterwards, rats were put into three groups with equal numbers. The groups were labelled as the control, the PDTC and the bortezomib groups. Seven days after treatment, a third laparotomy was done and the volume of implants was measured again. The animals were then sacrificed, and the implants were stained with Ki67, proliferating cell nuclear antigen (PCNA), CD34, CD31 and Masson's trichrome histochemical staining. RESULTS: In 80% of the implanted rats, vesicles at the suture region were observed, and the rats graded according to average vesicle diameter (D) as: Grade 1 (no vesicle, 20% of rats), Grade 2 (D < 2 mm, 33.3% of rats), Grade 3 (2 mm < D > 4.5 mm, 26.7% of rats) and Grade 4 (D > 4.5 mm, 20% of rats). After treatment with PDTC or bortezomib, these percentages were decreased for Grades 3 and 4, and increased in Grade 1. The post-treatment implant volumes were decreased in the PDTC and bortezomib groups (P < 0.002 and P < 0.001), and slightly increased in the control group (P = 0.279). In the PDTC and bortezomib groups, CD34, CD31, PCNA and Ki67 expression levels were similar but were significantly reduced compared with the control group. CONCLUSIONS: PDTC and bortezomib may represent a novel therapeutic strategy for treatment of endometriosis.en_US
dc.description.sponsorshipESHREen_US
dc.identifier.doi10.1093/humrep/den246
dc.identifier.endpage2465en_US
dc.identifier.issn0268-1161
dc.identifier.issn1460-2350
dc.identifier.issue11en_US
dc.identifier.pmid18676981en_US
dc.identifier.scopus2-s2.0-54149113179en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2458en_US
dc.identifier.urihttps://doi.org/10.1093/humrep/den246
dc.identifier.urihttps://hdl.handle.net/11616/94672
dc.identifier.volume23en_US
dc.identifier.wosWOS:000260142900009en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofHuman Reproductionen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNF-kappa B inhibitoren_US
dc.subjectproteasome inhibitoren_US
dc.subjectinflammationen_US
dc.subjectendometriosisen_US
dc.titleCombating endometriosis by blocking proteasome and nuclear factor-?B pathwaysen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu